- Home
- SNAL vs RLYB Comparison
SNAL vs RLYB Comparison
Compare SNAL & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNAL | RLYB |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8M | 28.7M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SNAL | RLYB |
|---|---|---|
| Price | $0.72 | $10.95 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.4K | ★ 235.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 27.72 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $84,467,047.00 | $600,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | $50.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 38.69 | N/A |
| 52 Week Low | $0.58 | $0.22 |
| 52 Week High | $2.15 | $11.49 |
Technical Indicators
Market Signals| Indicator | SNAL | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 91.44 |
| Support Level | $0.58 | $0.48 |
| Resistance Level | $0.71 | N/A |
| Average True Range (ATR) | 0.04 | 0.78 |
| MACD | 0.01 | 0.41 |
| Stochastic Oscillator | 45.30 | 92.13 |
Price Performance
Historical ComparisonAbout SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.